Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly CEO, In Shanghai, Predicts Better Patent Protection Will Unleash Scientific Innovation Across China

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Calling the start of the new millennium "the century of human medicine," John Lechleiter, Eli Lilly's chief executive officer, predicted that Chinese scientists would help shape the era, but also said that the government needs to advance its intellectual property regime in order to unleash innovation
Advertisement

Related Content

After Running Lilly From China, CEO Says Local Commitment, Innovation Remain Priorities
After Running Lilly From China, CEO Says Local Commitment, Innovation Remain Priorities
Pfizer Banking On China's Emerging Neuropathic Pain Market For Lyrica
Pfizer Banking On China's Emerging Neuropathic Pain Market For Lyrica
Lilly And Queensland Government Invest In First-ever Australian Biotech VC Fund
Eli Lilly CEO John Lechleiter Rules Out Mega-merger Or Major Push Into Generics, Outlines Strategy Aimed At China's 21st Century Rise In An Interview With PharmAsia News
Roche, Novartis, Lilly, J&J: Earnings Call Roundup For Emerging Markets
Global Spread Of Technologies, West’s Economic Downturn And East’s Rise Will Fundamentally Change Pharma Giants By 2020
Hutchison MediPharma and Eli Lilly Sign New Discovery Deal
Hutchison MediPharma and Eli Lilly Sign New Discovery Deal
Advertisement
UsernamePublicRestriction

Register

SC074591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel